SG11201907855QA - Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 - Google Patents
Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2Info
- Publication number
- SG11201907855QA SG11201907855QA SG11201907855QA SG11201907855QA SG11201907855QA SG 11201907855Q A SG11201907855Q A SG 11201907855QA SG 11201907855Q A SG11201907855Q A SG 11201907855QA SG 11201907855Q A SG11201907855Q A SG 11201907855QA SG 11201907855Q A SG11201907855Q A SG 11201907855QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- february
- ano1
- trop2
- claudin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIPO I PCT onion °nolo OH loom DID Ho Imo oimIE (10) International Publication Number WO 2018/157147 Al (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/46 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/019999 (22) International Filing Date: 27 February 2018 (27.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/464,347 27 February 2017 (27.02.2017) US 62/464,344 27 February 2017 (27.02.2017) US 62/464,341 27 February 2017 (27.02.2017) US 62/467,557 06 March 2017 (06.03.2017) US 62/473,652 20 March 2017 (20.03.2017) US 62/473,659 20 March 2017 (20.03.2017) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (71) Applicant: DRAGONFLY THERAPEUTICS, INC. [US/US]; 35 Gatehouse Drive, Waltham, MA 02451 (US). (72) Inventors: CHANG, Gregory, P.; 143 Saunders Street, Medford, MA 02155 (US). CHEUNG, Ann, F.; 25 Morn- ingside Lane, Lincoln, MA 01773 (US). GUTIERREZ, Eva; 67 Hillcrest Street, Waltham, MA 02451 (US). HANEY, William; 61 Lincoln Road, Wayland, MA 01778 (US). LUNDE, Bradley, M.; 7 Lucent Drive, Lebanon, NH 03766 (US). PRINZ, Bianka; 7 Lucent Drive, Lebanon, NH 03766 (US). (74) Agent: ASHRAF, Shovon et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: MULTISPECIFIC BINDING PROTEINS TARGETING CAIX, ANO1, MESOTHELIN,TROP2, CEA, OR CLAUDIN-18.2 FIG. 1 (57) : Multi-specific binding proteins that bind the NKG2D receptor, CD 16, and a tumor-associated antigen selected from carbonic anhydrase 9 (CAIX), anoctamin-1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2 are described, as well as pharmaceutical composi- tions and therapeutic methods useful for the treatment of cancer. W O 20 18/ 157147 A
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464341P | 2017-02-27 | 2017-02-27 | |
US201762464344P | 2017-02-27 | 2017-02-27 | |
US201762464347P | 2017-02-27 | 2017-02-27 | |
US201762467557P | 2017-03-06 | 2017-03-06 | |
US201762473659P | 2017-03-20 | 2017-03-20 | |
US201762473652P | 2017-03-20 | 2017-03-20 | |
PCT/US2018/019999 WO2018157147A1 (en) | 2017-02-27 | 2018-02-27 | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907855QA true SG11201907855QA (en) | 2019-09-27 |
Family
ID=63254067
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011219YA SG10202011219YA (en) | 2017-02-27 | 2018-02-27 | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 |
SG11201907855QA SG11201907855QA (en) | 2017-02-27 | 2018-02-27 | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202011219YA SG10202011219YA (en) | 2017-02-27 | 2018-02-27 | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20210130496A1 (en) |
EP (2) | EP3800203A1 (en) |
JP (3) | JP7286543B2 (en) |
KR (2) | KR20190123299A (en) |
CN (2) | CN112661853A (en) |
AU (2) | AU2018224319B2 (en) |
BR (1) | BR112019017758A2 (en) |
CA (3) | CA3054738A1 (en) |
IL (1) | IL268888A (en) |
MX (2) | MX2019010156A (en) |
RU (1) | RU2020137306A (en) |
SG (2) | SG10202011219YA (en) |
WO (1) | WO2018157147A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110944651A (en) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | Multispecific binding proteins for natural killer cell activation and therapeutic uses thereof for treating cancer |
FI3582806T3 (en) | 2017-02-20 | 2023-09-07 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
AU2018331412A1 (en) * | 2017-09-14 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16, and C-type lectin-like molecule-1 (CLL-1) |
SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
WO2020238730A1 (en) * | 2019-05-24 | 2020-12-03 | 三优生物医药(上海)有限公司 | Novel cldn18.2 binding molecule |
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
CN112552408B (en) * | 2019-09-10 | 2022-09-20 | 普米斯生物技术(珠海)有限公司 | Nano antibody targeting CAIX antigen and application thereof |
KR20220119621A (en) * | 2019-12-27 | 2022-08-30 | 난징 레전드 바이오테크 씨오., 엘티디. | CLAUDIN18.2 binding moieties and uses thereof |
US20210269551A1 (en) * | 2020-02-25 | 2021-09-02 | Gensun Biopharma Inc. | Trispecific T cell Engagers |
CN113527497B (en) * | 2020-04-16 | 2022-06-10 | 上海洛启生物医药技术有限公司 | anti-Trop 2 nano antibody and application thereof |
CN116234821A (en) * | 2020-07-02 | 2023-06-06 | 吉加根公司 | anti-CTLA-4 binding proteins and methods of use thereof |
CN111777681B (en) * | 2020-07-06 | 2022-10-11 | 康诺亚生物医药科技(成都)有限公司 | Antibody combined with tight junction protein-18.2 and application thereof |
CN112321715B (en) * | 2020-11-03 | 2022-05-10 | 博奥信生物技术(南京)有限公司 | anti-TROP 2 nano antibody and preparation method and application thereof |
TWI825544B (en) * | 2020-12-31 | 2023-12-11 | 大陸商信達生物製藥(蘇州)有限公司 | Protein containing heterodimer antibody fc and preparation method thereof |
CN113583091B (en) * | 2021-07-26 | 2023-05-26 | 郑州大学第一附属医院 | Specific targeting polypeptide of immunosuppressive cell tight junction protein and application thereof |
CN113801231B (en) * | 2021-08-20 | 2022-09-02 | 四川大学华西医院 | anti-DOG-1 antibodies or antigen-binding fragments thereof and uses thereof |
WO2024068572A1 (en) * | 2022-09-28 | 2024-04-04 | F. Hoffmann-La Roche Ag | Improved protease-activatable t cell bispecific antibodies |
CN115969997B (en) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | Antibody drug conjugate targeting CLDN18.2 and application thereof |
CN116814664B (en) * | 2023-08-25 | 2023-12-12 | 中国医学科学院肿瘤医院 | Preparation and application of CEA chimeric antigen receptor T cells for expanding tumor recognition epitope |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2871905T3 (en) * | 2002-03-01 | 2021-11-02 | Immunomedics Inc | Immunoconjugate comprising humanized RS7 antibodies |
AU2007257692B2 (en) * | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
DK2222706T4 (en) * | 2007-12-14 | 2016-11-21 | Novo Nordisk As | Antibodies that bind to NKG2D and its use |
US9273136B2 (en) * | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CN101928347B (en) * | 2010-05-05 | 2013-03-27 | 上海海抗中医药科技发展有限公司 | Anti-carcinoembryonic-antigen (CEA) antibody and application thereof |
PL2635607T3 (en) * | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
CN107903325B (en) * | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | Multispecific FAB fusion proteins and methods of use thereof |
WO2013187495A1 (en) * | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
US10968276B2 (en) * | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
HUE047925T2 (en) * | 2013-02-26 | 2020-05-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules specific to cd3 and cea |
US10156574B2 (en) * | 2013-04-29 | 2018-12-18 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
EP3406633B1 (en) * | 2013-07-25 | 2022-03-02 | Cytomx Therapeutics Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
CN106573050B (en) * | 2014-05-29 | 2021-09-24 | 宏观基因有限公司 | Trispecific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
US20180318417A1 (en) * | 2015-01-14 | 2018-11-08 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
WO2016134371A2 (en) | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
EP3307282A4 (en) * | 2015-06-12 | 2019-05-01 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
EP3313876A2 (en) * | 2015-06-23 | 2018-05-02 | Innate Pharma | Multispecific antigen binding proteins |
-
2018
- 2018-02-27 EP EP20207020.7A patent/EP3800203A1/en active Pending
- 2018-02-27 SG SG10202011219YA patent/SG10202011219YA/en unknown
- 2018-02-27 KR KR1020197027877A patent/KR20190123299A/en not_active Application Discontinuation
- 2018-02-27 WO PCT/US2018/019999 patent/WO2018157147A1/en active Application Filing
- 2018-02-27 CA CA3054738A patent/CA3054738A1/en active Pending
- 2018-02-27 CN CN202011255954.9A patent/CN112661853A/en active Pending
- 2018-02-27 US US16/488,395 patent/US20210130496A1/en not_active Abandoned
- 2018-02-27 CA CA3177692A patent/CA3177692A1/en active Pending
- 2018-02-27 AU AU2018224319A patent/AU2018224319B2/en active Active
- 2018-02-27 SG SG11201907855QA patent/SG11201907855QA/en unknown
- 2018-02-27 KR KR1020207032594A patent/KR20200130514A/en not_active Application Discontinuation
- 2018-02-27 RU RU2020137306A patent/RU2020137306A/en unknown
- 2018-02-27 MX MX2019010156A patent/MX2019010156A/en unknown
- 2018-02-27 EP EP18756655.9A patent/EP3585424A4/en active Pending
- 2018-02-27 CN CN201880028256.XA patent/CN110662555A/en active Pending
- 2018-02-27 BR BR112019017758A patent/BR112019017758A2/en unknown
- 2018-02-27 CA CA3099179A patent/CA3099179A1/en active Pending
- 2018-02-27 JP JP2019546295A patent/JP7286543B2/en active Active
-
2019
- 2019-08-25 IL IL26888819A patent/IL268888A/en unknown
- 2019-08-26 MX MX2020012130A patent/MX2020012130A/en unknown
-
2020
- 2020-11-11 AU AU2020267226A patent/AU2020267226A1/en active Pending
- 2020-11-11 US US17/095,238 patent/US20210130474A1/en active Pending
- 2020-11-11 JP JP2020188115A patent/JP7187518B2/en active Active
-
2022
- 2022-11-30 JP JP2022191804A patent/JP2023029927A/en active Pending
-
2023
- 2023-02-08 US US18/107,292 patent/US20230391877A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020012130A (en) | 2021-01-29 |
JP2023029927A (en) | 2023-03-07 |
EP3585424A1 (en) | 2020-01-01 |
US20210130474A1 (en) | 2021-05-06 |
RU2020137306A (en) | 2021-01-12 |
CN112661853A (en) | 2021-04-16 |
AU2018224319B2 (en) | 2024-04-04 |
RU2019130323A (en) | 2021-03-29 |
EP3585424A4 (en) | 2021-01-13 |
CN110662555A (en) | 2020-01-07 |
US20230391877A1 (en) | 2023-12-07 |
KR20200130514A (en) | 2020-11-18 |
KR20190123299A (en) | 2019-10-31 |
JP7286543B2 (en) | 2023-06-05 |
BR112019017758A2 (en) | 2020-04-07 |
IL268888A (en) | 2019-10-31 |
AU2020267226A1 (en) | 2020-12-10 |
EP3800203A1 (en) | 2021-04-07 |
RU2019130323A3 (en) | 2021-06-21 |
SG10202011219YA (en) | 2020-12-30 |
AU2018224319A1 (en) | 2019-09-12 |
US20210130496A1 (en) | 2021-05-06 |
WO2018157147A1 (en) | 2018-08-30 |
CA3177692A1 (en) | 2018-08-30 |
MX2019010156A (en) | 2020-01-09 |
CA3099179A1 (en) | 2018-08-30 |
JP2021035388A (en) | 2021-03-04 |
CA3054738A1 (en) | 2018-08-30 |
JP2020510653A (en) | 2020-04-09 |
JP7187518B2 (en) | 2022-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
SG11201907638QA (en) | Proteins binding cd33, nkg2d and cd16 | |
SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
SG11201804934PA (en) | Novel Compounds | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201907271PA (en) | Proteins binding psma, nkg2d and cd16 | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201907648XA (en) | Proteins binding gd2, nkg2d and cd16 | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use |